[Adrenokortikal Karsinomlarda Tedavi Ve İzlem]

Adrenokortikal karsinom nadir görülen bir endokrin malignitedir. Hastalar hormon aşırı salınımına veya kitlenin lokal etkisine bağlı semptomlar ile başvurur. Agressif bir tümördür ve nüks riski kitlenin tam rezeksiyonuna rağmen yüksektir. Başta lokal nüks olmak üzere nüks gelişme oranı laparoskopik adrenalektomi sonrası daha sıktır ve özellikle operasyon sonrası ilk iki yıl içinde gözlenir. Yüksek nüks oranları nedeniyle çoğu hasta radikal rezeksiyon sonrası adjuvan tedaviye ihtiyaç duyar. Adjuvan tedavide üç yaklaşım önerilir: Mitotan, mitotan-kemoterapotik ilaç kombinasyonu ve tümör yatağına radyoterapi. Adjuvan mitotan medikal tedavide birinci basamaktır. Ancak yan etkileri mevcuttur ve terapotik aralığının dar olması nedeniyle yakın takip gerektirir. Yan etkiler ilaç dozunun azaltılmasıyla kontrol altına alınabilir. Adrenokortikal karsinomlu hastalar radikal cerrahi sonrası en az 10 yıl olmak üzere düzenli takip edilmelidir

Anahtar Kelimeler:

Adrenal kanser, tedavi, cerrahi, mitotan, kemoterapi, radyoterapi

The Treatment and Follow up of Adrenocortical Carcinoma [Adrenokortikal Karsinomlarda Tedavi Ve İzlem]

AbstractAdrenocortical carcinoma is a rare endocrine malignancy. Patients present with hormone excess or a local mass effect. The tumor is agressive and characterized by a high risk of recurrence even after complete resection. Recurrence rate (particularly local recurrence) is higher in laparoscopic adrenalectomy and most recurrences occur in the postoperative first two years. Because of the high recurrence rates, most patients need adjuvan treatment after radical resection. Three adjuvant therapotic approach have been suggested: Mitotane, mitotane plus chemotherapeutic agents and radiotherapy of the tumor bed. Adjuvant mitotane is the first line medical treatment but it is associated with some adverse events and in all patients a strict follow up is required because of the drug’s narrow therapeutic index. Adverse events are manageable through reduction of the mitotane dose. Patients with adrenocortical carcinoma should be followed up regularly at least 10 years after radical surgery. Key Words: Adrenal cancer, treatment, surgery, mitotane, chemotherapy, radiotherapyÖzetAdrenokortikal karsinom nadir görülen bir endokrin malignitedir. Hastalar hormon aşırı salınımına veya kitlenin lokal etkisine bağlı semptomlar ile başvurur. Agressif bir tümördür ve nüks riski kitlenin tam rezeksiyonuna rağmen yüksektir. Başta lokal nüks olmak üzere nüks gelişme oranı laparoskopik adrenalektomi sonrası daha sıktır ve özellikle operasyon sonrası ilk iki yıl içinde gözlenir. Yüksek nüks oranları nedeniyle çoğu hasta radikal rezeksiyon sonrası adjuvan tedaviye ihtiyaç duyar. Adjuvan tedavide üç yaklaşım önerilir: Mitotan, mitotan-kemoterapotik ilaç kombinasyonu ve tümör yatağına radyoterapi. Adjuvan mitotan medikal tedavide birinci basamaktır. Ancak yan etkileri mevcuttur ve terapotik aralığının dar olması nedeniyle yakın takip gerektirir. Yan etkiler ilaç dozunun azaltılmasıyla kontrol altına alınabilir. Adrenokortikal karsinomlu hastalar radikal cerrahi sonrası en az 10 yıl olmak üzere düzenli takip edilmelidir. Anahtar Kelimeler: Adrenal kanser, tedavi, cerrahi, mitotan, kemoterapi, radyoterapi

Keywords:

-,

PDF

___

Michalkiewicz E, Sandrini R, Figueiredo B, Mianda EC, Caran E, Oliveira-Filho AG, Marques R, Pianovski MA, Lacerda L, Cristofani LM, Jenkins J, Rodrigues-Galindo C, Ribeiro RC. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol. 2004;22(5):838-45.
Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, Pentheroudakis G; ESMO Guidelines Working Group. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol. 2012;23(Suppl 7):vii131-8.
Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A. Adjuvan mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372-80.
Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B; German Adrenocortical Carcinoma Registry Group; European Network for the Study of Adrenal Tumors. German adrenocortical carcinoma registry group; European Network for the Study of Adrenal Tumors. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009;115(2):243-50.
Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;91(6):2027-37.
Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg. 2001;25(7):914-26.
Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, Langer P, Mussack T, Nies C, Riedmiller H, Spahn M, Weismann D, Hahner S, Fassnacht M; German Adrenocortical Carcinoma Registry Group. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol. 2010;58(4):609-15.
Porpiglia F, Fiori C, Daffara F, Zaggia B, Bollito E, Volante M, Berruti A, Terzolo M. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol. 2010;57(5):873-8.
Donatini G, Caiazzo R, Do Cao C, Aubert S, Zerrweck C, El-Kathib Z, Gauthier T, Leteurtre E, Wemeau JL, Vantyghem MC, Carnaille B, Pattou F. Long term survival after adrenalectomy for stage I/II Adrenocortical carcinoma (ACC): Retrospective comparative cohort study of laparoscopic versus open approch. Ann Surg Oncol. 2014;21(1):284-91.
Leboulleux S, Deandreis D, Al Ghuzlan A, Auperin A, Goere D, Dromain C, Elias D, Caillou B, Travagli JP, De Baere T, Lumbroso J, Young J, Schlumberger M, Baudin E. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol. 2010;162(6):1147-53.
Cooper AB, Habra MA, Grubbs EG, Bednarski BK, Ying AK, Perrier ND, Lee JE, Aloia TA. Surg Endosc. 2013;27(11):4026-32.
Nelson AA, Woodard G. Adrenal cortical atrophy and liver damage produced in dogs by feding 2,2-bis (parachloro-phenyl)-1,1-dichloroethane. Fed Proc. 1948;7(1 Pt 1):277.
Bergenstal DM, Hertz R, Lipsett MB, Moy RH. Chemotherapy of adrenocortical cancer with o,p’-DDD. Ann Int Med. 1960;53:672-82.
Touitou Y, Bogdan A, Luton JP. Changes in corticosteroid synthesis of the human adrenal cortex in vitro, induced by treatment with o,p'-DDD for Cushing's syndrome: evidence for the sites of action of the drug. J Steroid Biochem. 1978;9(12):1217-24.
Heilmann P, Wagner P, Nawroth PP, Ziegler R. [Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels]. Med Klin (Munich). 2001 15;96(7):371-7.
Phan AT. Adrenal cortical carcinoma--review of current knowledge and treatment practices. Hematol Oncol Clin North Am. 2007;21(3):489-507; viii-ix.
Heak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, Krans HM. Optimal treatment of adrenocortical carcinoma with mitotane: Results in consecutive series of 96 patients. Br J Cancer. 1994;69(5):947-51.
Faggiano A, Del Prete M, Marciello F, Marotta V, Ramundo V, Colao A. Thyroid disease in ederly. Minerva Endocrinol. 2011;36(3):211-31.
Yeung SC, Chiu AC, Vassilopou-Sellin R, Gagel RF. The endocrine effects of nonhormonal antineoplastic theraphy. Endocr Rev. 1998;19(2):144-77.
Kasperlik-Zaluska AA, Migdalska BM, Zgliczynski S, Makowska AM. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer. 1995;75(10):2587-91.
Schteingart DE. Adjuvant mitotane therapy of adrenal cancer - use and controversy. N Engl J Med. 2007;356(23):2415-8.
Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, Fuhrer D, Jurowich C, Quinkler M, Petersenn S, Spahn M, Hahner S, Allolio B. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab. 2010;95(11):4925-32.
Wangberg B, Khorram-Manesh A, Jansson S, Nilsson B, Nilsson O, Jakobsson CE, Lindstedt S, Oden A, Ahlman H. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer. 2010;17(1):265-72.
Maluf DF, Oliveria BH, Lalli E. Therapy of adrenocortical cancer: present and future. Am J Cancer Res. 2011;1(2):222-32.
Vassilopoulou-Sellin R, Guinee VF, Klein MJ, Taylor SH, Hess KR, Schultz PN, Samaan NA. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer. 1993;71(10):3119-23.
Bertherat J, Coste J, Bertagna X. Adjuvant mitotane in adrenocortical carcinoma. N Engl J Med. 2007;357(12):1256-7; author reply 1259.
Terzolo M, Berruti A. Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes. 2008;15(3):221-6.
Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocotical carcinoma: a clinician’s update. Nat Rev Endocrinol. 2011;7(6):323-35.
Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 2005;12:657-66.